Therapeutic regimen for treating cancer comprising the...

Details Therapeutic regimen for treating cancer comprising the... Therapeutic regimen for treating cancer comprising the...

2007-05-08

2007-05-08

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C514S04400A, C435S320100, C536S023100, C536S023520, C536S024100, C800S021000

Reexamination Certificate

active

10151633

ABSTRACT:
The invention provides a method for treating a tumor in a human comprising administering to the tumor a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about 1×107to about 4×1012particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the tumor in human is treated.

REFERENCES:
patent: 4879226 (1989-11-01), Wallace et al.
patent: 5206152 (1993-04-01), Sukhatme
patent: 5288852 (1994-02-01), Yamada et al.
patent: 5324655 (1994-06-01), Kriegler et al.
patent: 5422104 (1995-06-01), Fiers et al.
patent: 5571797 (1996-11-01), Ohno et al.
patent: 5612318 (1997-03-01), Weichselbaum et al.
patent: 5624830 (1997-04-01), Mullen et al.
patent: 5641755 (1997-06-01), Weichselbaum et al.
patent: 5652353 (1997-07-01), Fiers et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5763209 (1998-06-01), Sukhatme
patent: 5770581 (1998-06-01), Weichselbaum et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5817636 (1998-10-01), Weichselbaum et al.
patent: 5846945 (1998-12-01), McCormick
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5856181 (1999-01-01), McCormick
patent: 5863797 (1999-01-01), Kriegler et al.
patent: 5962424 (1999-10-01), Hallahan et al.
patent: 5968735 (1999-10-01), Stein et al.
patent: 5972706 (1999-10-01), McCormick
patent: 5993800 (1999-11-01), Linsley et al.
patent: 6066624 (2000-05-01), Woo et al.
patent: 6254862 (2001-07-01), Little et al.
patent: 6271207 (2001-08-01), Cristiano et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6297219 (2001-10-01), Nabel et al.
patent: 6337338 (2002-01-01), Kozlowski et al.
patent: 197 47 718 (1999-05-01), None
patent: 0 155 549 (1985-09-01), None
patent: 0 869 180 (1998-10-01), None
patent: WO 92/11033 (1992-07-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 94/06916 (1994-03-01), None
patent: WO 94/21792 (1994-09-01), None
patent: WO 95/06120 (1995-03-01), None
patent: WO 95/34671 (1995-12-01), None
patent: WO 96/27021 (1996-09-01), None
patent: WO 96/33746 (1996-10-01), None
patent: WO 97/12623 (1997-04-01), None
patent: WO 97/20051 (1997-06-01), None
patent: WO 98/00166 (1998-01-01), None
patent: WO 98/46779 (1998-10-01), None
patent: WO 98/46781 (1998-10-01), None
patent: WO 98/55622 (1998-12-01), None
patent: WO 99/00518 (1999-01-01), None
patent: WO 99/16889 (1999-04-01), None
patent: WO 99/21589 (1999-05-01), None
patent: WO 99/23216 (1999-05-01), None
patent: WO 99/46371 (1999-09-01), None
patent: WO 99/47690 (1999-09-01), None
patent: WO 99/55831 (1999-11-01), None
patent: WO 99/65515 (1999-12-01), None
patent: WO 00/14255 (2000-03-01), None
patent: WO 00/23088 (2000-04-01), None
patent: WO 00/39319 (2000-07-01), None
patent: WO 00/44922 (2000-08-01), None
patent: WO 01/24684 (2001-04-01), None
patent: WO 02/00906 (2002-01-01), None
patent: WO 02/080849 (2002-10-01), None
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Luo, et al. (2004) Trends in Biotechnology, 22(3): 101-03.
Somia, et al. (2000) Nature Reviews: Genetics, “Gene Therapy: Trials and Tribulations”, 1: 91-99.
Hallahan et al.,Am. J. Clin. Oncol., 24 (5), 473-480 (2001).
Kurihara et al.,J. Clin. Invest., 106(6), 763-771 (Sep. 2000).
Weichselbaum et al.,Lancet Oncol., 3, 665-671 (Nov. 2002).
Baher et al.,Anticancer Research, 19 (4B), 2917-2924 (Jul.-Aug. 1999).
Blankenstein et al.,J. Exp. Med., 173, 1047-1052 (1991).
Block et al.,Arch. Surg., 127, 1330-1334 (1992).
Brough et al.,J. Virol., 70 (9), 6497-6501 (1996).
Chung et al.,Cancer Gene Ther., 5 (6), 344-349 (1998).
Creaven et al.,Cancer Chemother. Pharmacol., 20, 137-144 (1987).
Eggermont et al.,Ann. Surg., 224 (6), 756-765 (1996).
Fiers et al.,Proc. Am. Assoc. Cancer Res., 34, 581-582 (1993).
Fujii et al.,Blood, 93 (12), 4328-4335 (1999).
Ginsberg et al.,Bull. New York Acad. Med., 73 (1), 53-58 (1996).
Gridley et al.,Anticancer Res., 14, 1107-1112 (1994).
Gridley et al.,Anticancer Res., 20 (6B), 4195-4203 (Nov.-Dec. 2000).
Gridley et al.,Oncol. Res., 9, 217-227 (1997).
Hallahan et al.,Nat. Med., 1 (8), 786-791 (1995).
Hallahan et al.,Proceedings of ASCO, 15, p. 84, Abstract 3, (1996).
Haranaka et al.,Int. J. Cancer, 34, 263-267 (1984).
Hersh et al.,Gene Ther., 2, 124-131 (1995).
Hu et al.,Cancer Res., 57, 3339-3343 (1997).
Isobe et al.,Biochem. Biomed. Res. Comm., 202 (3), 1538-1542 (1994).
Jones et al.,Cancer Surveys, 8 (4), 817-836 (1989).
Jones et al.,Progress in Growth Factor Res., 1, 107-122 (1989).
Koshita et al.,Int. J. Cancer, 63, 130-135 (1995).
Lejeune,Eur. J. Cancer, 31A (6), 1109-1016 (1995).
Leonard et al.,J. Urol., 148, 743-746 (1992).
Manusama et al.,Seminars in Surgical Oncology, 14, 232-237 (1998).
Marr et al.,Cancer Gene Ther., 6 (5), 465-474 (1998).
Marr et al.,Gene Ther., 4, 1181-1188 (1997).
Marr et al.,Int. J. Onconology, 12, 509-515 (1998).
Martinet et al.,Am. J. Respir. Cell Mol. Biol., 6, 510-515 (1992).
Mauceri et al.,C. R. Acad. Sci. Series III, 322 (2-3), 225-228 (Feb. 1999).
Mauceri et al.,Cancer Res., 56, 4311-4314 (1996).
Mauceri et al.,Proc. Am. Assoc. Cancer Res., 37, p. 347, Abstract 2365, (1996).
Mauceri et al.,Radiation Oncology Investigations, 5, 220-226 (1997).
Morsy et al.,PNAS USA, 95, 7866-7871 (Jul. 1998).
Mulé,Proc. Am. Assoc. Cancer Res., 34, 581 (1993).
Porter,Trends in Biotechnology, 9, 158-162 (1991).
Richards et al.,Ann. New York Acad. Sci., 762, 282-293 (1995).
Sata et al.,Cancer Res., 58, 1677-1683 (1998).
Sersa et al.,Int. J. Cancer, 42, 129-134 (1988).
Seung et al.,Cancer Res., 55, 5561-5565 (1995).
Slesarev et al.,Medical Oncology, 15, 37-43 (1998).
Sparmann et al.,Int. J. Cancer, 59, 103-107 (1994).
Spriggs et al.,in: Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, Chapter 25, 383-406 (Raven Press, Ltd., New York, NY, 1992).
Spriggs et al.,J. Nat. Cancer Inst., 80 (13), 1039-1044 (1988).
Staba et al.,Gene Ther., 5, 293-300 (1998).
Standiford et al.,Human Gene Ther., 10, 899-909 (1999).
Wakabayashi et al.,Neurol. Med. Chir.(Tokyo), 37, 739-746 (1997).
Weichselbaum et al.,Cancer Res., 54, 4266-4269 (1994).
Whartenby et al.,Drugs, 50 (6), 951-958 (1995).
Wright et al.,Cancer Gene Ther., 5 (6), 371-379 (1998).
Donnelly et al.,Radiology, 219 (1), 166-170 (Apr. 2001).
Sharma et al.,Hum. Gene Ther., 12, 1109-1131 (Jun. 10, 2001).
Crystal et al.,Hum. Gene Ther., 13 (1), 65-100 (Jan. 1, 2002).
Harvey et al.,Hum, Gene Ther., 13 (1), 15-63 (Jan. 1, 2002).
Mundt et al.,Clin. Cancer Res., 10 (17), 5747-5753 (Sep. 1, 2004).
Senzer et al.,J. Clin. Oncol., 22 (4), 592-601 (Feb. 15, 2004).

Affiliated with

Also associated with

Rating

Therapeutic regimen for treating cancer comprising the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic regimen for treating cancer comprising the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic regimen for treating cancer comprising the... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3799696